相似文献
1
Neuroimaging in Vascular Parkinsonism.
Curr Neurol Neurosci Rep. 2019 Nov 26;19(12):102. doi: 10.1007/s11910-019-1019-7.
2
Minimal parkinsonism in the elderly is associated with striatal dopamine loss and pontine structural damage.
Parkinsonism Relat Disord. 2020 Dec;81:140-143. doi: 10.1016/j.parkreldis.2020.10.038. Epub 2020 Oct 27.
3
F-FP-CIT dopamine transporter PET findings in cirrhotic patients with parkinsonism.
Neurotoxicology. 2018 Jan;64:78-84. doi: 10.1016/j.neuro.2017.02.014. Epub 2017 Mar 1.
4
A Japanese Encephalitis Patient Presenting with Parkinsonism with Corresponding Laterality of Magnetic Resonance and Dopamine Transporter Imaging Findings.
Intern Med. 2018 Aug 1;57(15):2243-2246. doi: 10.2169/internalmedicine.0337-17. Epub 2018 Mar 9.
5
Imaging of the dopamine transporter predicts pattern of disease progression and response to levodopa in patients with schizophrenia and parkinsonism: a 2-year follow-up multicenter study.
Schizophr Res. 2014 Feb;152(2-3):344-9. doi: 10.1016/j.schres.2013.11.028. Epub 2013 Dec 25.
6
Deep learning regressor model based on nigrosome MRI in Parkinson syndrome effectively predicts striatal dopamine transporter-SPECT uptake.
Neuroradiology. 2023 Jul;65(7):1101-1109. doi: 10.1007/s00234-023-03168-z. Epub 2023 May 20.
7
The clinical benefit of imaging striatal dopamine transporters with [123I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism.
Eur J Nucl Med. 2001 Mar;28(3):266-72. doi: 10.1007/s002590000460.
8
Clinical utility and research frontiers of neuroimaging in movement disorders.
Q J Nucl Med Mol Imaging. 2017 Dec;61(4):372-385. doi: 10.23736/S1824-4785.17.03018-7. Epub 2017 Aug 28.
9
Decreased striatal dopamine transporter uptake and substantia nigra hyperechogenicity as risk markers of synucleinopathy in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study [corrected].
Lancet Neurol. 2010 Nov;9(11):1070-7. doi: 10.1016/S1474-4422(10)70216-7. Epub 2010 Sep 16.
10
Correlation between neuromelanin-sensitive MR imaging and (123)I-FP-CIT SPECT in patients with parkinsonism.
Neuroradiology. 2016 Apr;58(4):351-6. doi: 10.1007/s00234-016-1644-7. Epub 2016 Jan 16.
引用本文的文献
1
Vascular parkinsonism: an update.
J Neural Transm (Vienna). 2025 Jun 5. doi: 10.1007/s00702-025-02960-w.
2
The Utilization and Impact of Dopamine Transporter Imaging in Diagnosing Movement Disorders at a Tertiary Care Hospital in Greece.
Biomedicines. 2025 Apr 16;13(4):970. doi: 10.3390/biomedicines13040970.
3
Vascular parkinsonism showing dopamine transporter scan findings mimicking those of Parkinson's disease.
eNeurologicalSci. 2024 Sep 18;37:100528. doi: 10.1016/j.ensci.2024.100528. eCollection 2024 Dec.
4
Atypical Parkinsonian Syndromes: Structural, Functional, and Molecular Imaging Features.
AJNR Am J Neuroradiol. 2024 Dec 9;45(12):1865-1877. doi: 10.3174/ajnr.A8313.
5
Preservation of Dopamine Transporters in a Patient With Micrographia Due to Cerebral Infarction: A Case Report.
J Mov Disord. 2023 May;16(2):221-223. doi: 10.14802/jmd.23033. Epub 2023 May 24.
6
Parkinsonism Is Associated with Altered SMA-Basal Ganglia Structural and Functional Connectivity in Frontotemporal Degeneration.
Biomedicines. 2023 Feb 10;11(2):522. doi: 10.3390/biomedicines11020522.
7
The correlation between enlarged perivascular spaces and cognitive impairment in Parkinson's disease and vascular parkinsonism.
BMC Neurol. 2022 Jul 29;22(1):282. doi: 10.1186/s12883-022-02819-7.
8
Dopamine Transporter Imaging, Current Status of a Potential Biomarker: A Comprehensive Review.
Int J Mol Sci. 2021 Oct 18;22(20):11234. doi: 10.3390/ijms222011234.
9
Aberrant Neurogliovascular Unit Dynamics in Cerebral Small Vessel Disease: A Rheological Clue to Vascular Parkinsonism.
Pharmaceutics. 2021 Aug 5;13(8):1207. doi: 10.3390/pharmaceutics13081207.
10
Mind the Gap: LRRK2 Phenotypes in the Clinic vs. in Patient Cells.
Cells. 2021 Apr 22;10(5):981. doi: 10.3390/cells10050981.
本文引用的文献
1
Vascular Parkinsonism by Infarctions at Different Locations on 18F-FP-CIT PET/CT.
Clin Nucl Med. 2019 Nov;44(11):e627-e628. doi: 10.1097/RLU.0000000000002721.
2
Microstructural changes of normal-appearing white matter in Vascular Parkinsonism.
Parkinsonism Relat Disord. 2019 Jun;63:60-65. doi: 10.1016/j.parkreldis.2019.02.046. Epub 2019 Mar 1.
3
Early- and late-phase F-FP-CIT PET images in vascular parkinsonism due to midbrain infarct.
Neurol Sci. 2019 May;40(5):1089-1091. doi: 10.1007/s10072-018-3676-8. Epub 2018 Dec 7.
4
Widespread diffusion changes differentiate Parkinson's disease and progressive supranuclear palsy.
Neuroimage Clin. 2018;20:1037-1043. doi: 10.1016/j.nicl.2018.09.028. Epub 2018 Oct 4.
5
Arteriosclerotic Parkinsonism.
Edinb Med J. 1930 Apr;37(4):261-262.
6
An updated diagnostic approach to subtype definition of vascular parkinsonism - Recommendations from an expert working group.
Parkinsonism Relat Disord. 2018 Apr;49:9-16. doi: 10.1016/j.parkreldis.2017.12.030. Epub 2017 Dec 29.
7
F-FDG PET in Parkinsonism: Differential Diagnosis and Evaluation of Cognitive Impairment.
J Nucl Med. 2017 Dec;58(12):1888-1898. doi: 10.2967/jnumed.116.186403. Epub 2017 Sep 14.
8
Evaluation of Parkinson's disease by neuromelanin-sensitive magnetic resonance imaging and I-FP-CIT SPECT.
Acta Radiol. 2018 May;59(5):593-598. doi: 10.1177/0284185117722812. Epub 2017 Jul 25.
9
MRI volumetric morphometry in vascular parkinsonism.
J Neurol. 2017 Jul;264(7):1511-1519. doi: 10.1007/s00415-017-8561-5. Epub 2017 Jul 1.
10
Drug-induced parkinsonism.
Mov Disord. 2017 Jul;32(7):1111. doi: 10.1002/mds.27050. Epub 2017 Jun 14.
Zotero 插件